Bristol Myers Squibb (CELG-RI) Income from Continuing Operations (2009 - 2026)

Bristol Myers Squibb (CELG-RI) posted quarterly Income from Continuing Operations of 2679000000.0 for Q1 2026, up 8.81% YoY from 2462000000.0 in Q1 2025, and up 146.69% sequentially from 1086000000.0 in Q4 2025.

Bristol Myers Squibb (CELG-RI) Income from Continuing Operations (2009 - 2026) Analysis & Trends

Bristol Myers Squibb has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 2679000000.0 for Q1 2026.

  • In Q1 2026, Income from Continuing Operations rose 8.81% year-over-year to 2679000000.0; the TTM figure through Mar 2026 stood at 7273000000.0 (up 33.77% YoY), while the FY2025 annual figure was 7056000000.0, up 178.99% from the prior year.
  • Income from Continuing Operations advanced to 2679000000.0 in Q1 2026, from 1086000000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CELG-RI reached as high as 2679000000.0 in Q1 2026 and fell as low as 11908000000.0 in Q1 2024.
  • The 5-year median for Income from Continuing Operations is 1684000000.0 (2024), against an average of 893352941.18.
  • Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 625.28% — and 2025, when it soared 1328.95%.
  • A 5-year view of Income from Continuing Operations shows it stood at 2025000000.0 in 2022, then dropped by 12.99% to 1762000000.0 in 2023, then tumbled by 95.69% to 76000000.0 in 2024, then soared by 1328.95% to 1086000000.0 in 2025, then soared by 146.69% to 2679000000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods registered 2679000000.0, 1086000000.0, and 2195000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 7.40 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 5.24 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 697.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 833.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -4.21 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 2.02 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 2.71 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn 2.68 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.68 Bn
Dec 31, 2025 1.09 Bn
Sep 30, 2025 2.20 Bn
Jun 30, 2025 1.31 Bn
Mar 31, 2025 2.46 Bn
Dec 31, 2024 76.00 Mn
Sep 30, 2024 1.22 Bn
Jun 30, 2024 1.68 Bn
Mar 31, 2024 -11.91 Bn
Dec 31, 2023 1.76 Bn
Sep 30, 2023 1.93 Bn
Jun 30, 2023 2.08 Bn
Mar 31, 2023 2.27 Bn
Dec 31, 2022 2.03 Bn
Sep 30, 2022 1.61 Bn
Jun 30, 2022 1.43 Bn
Mar 31, 2022 1.28 Bn
Dec 31, 2021 2.37 Bn
Sep 30, 2021 1.55 Bn
Jun 30, 2021 1.06 Bn